|
NY-ESO-1 serum and urine antibody status in patients with advanced
NY-ESO-1+ cancersa.
|
Patient
|
Primary Cancer
|
Metastases
|
Serum Ab
|
Urine Ab
|
|
NW29
|
melanoma
|
lymph
nodes
|
++
|
+
|
|
NW923
|
urothelial
|
liver
|
++
|
+
|
|
NW1073
|
soft
tissue sarcoma
|
liver
|
++
|
+
|
|
NW1106
|
melanoma
|
lung,
lymph nodes
|
++
|
+
|
|
NW1123
|
breast
|
lung,
liver
|
++
|
+
|
|
NW1231
|
thyroid
|
pleura
|
++
|
+
|
|
NW1288
|
stomach
|
liver
|
++
|
+
|
|
NW1310
|
breast
|
brain,
bone
|
++
|
+
|
|
NW1418
|
breast
|
skin,
lung
|
++
|
+
|
|
NW1453
|
melanoma
|
lymph
nodes
|
++
|
+
|
|
NW1474
|
leiomyosarcoma
|
peritoneum
|
++
|
+
|
|
NW1496
|
multiple
myeloma
|
bone
|
++
|
+
|
|
NW1539
|
melanoma
|
brain,
lymph node
|
++
|
+
|
|
NW1558
|
ovary
|
peritoneum
|
++
|
+
|
|
NW1567
|
ovary
|
peritoneum
|
++
|
+
|
|
NW1620
|
soft
tissue sarcoma
|
peritoneum
|
++
|
+
|
|
NW1622
|
NSCLC
|
liver
|
++
|
+
|
|
NW1624
|
stomach
|
lymph
nodes
|
++
|
+
|
|
NW1714
|
prostate
|
bone
|
++
|
+
|
|
NW1715
|
NSCLC
|
lung,
lymph nodes
|
++
|
+
|
|
NW1716
|
ovary
|
peritoneum
|
++
|
+
|
|
NW1241
|
NEC
|
liver
|
+
|
-
|
|
NW1312
|
NHL
|
lymph
nodes
|
+
|
-
|
|
NW1366
|
ovary
|
peritoneum
|
+
|
-
|
|
NW1374
|
SCLC
|
lung
|
+
|
-
|
|
NW1621
|
NSCLC
|
lung
|
+
|
-
|
|
NW1717
|
prostate
|
bone
|
+
|
-
|
|
NW1718
|
NSCLC
|
pleura,
lung
|
+
|
-
|
|
NW475
|
melanoma
|
lymph
nodes
|
-
|
-
|
|
NW555
|
melanoma
|
liver,
lung
|
-
|
-
|
|
NW597
|
melanoma
|
bone
|
-
|
-
|
|
NW846
|
soft
tissue sarcoma
|
lymph
nodes, bone
|
-
|
-
|
|
NW886
|
melanoma
|
lung
|
-
|
-
|
|
NW1045
|
melanoma
|
lung
|
-
|
-
|
|
NW1071
|
NSCLC
|
lung
|
-
|
-
|
|
NW1189
|
breast
|
lymph
nodes
|
-
|
-
|
|
NW1409
|
CAC
|
liver
|
-
|
-
|
|
NW1431
|
prostate
|
bone
|
-
|
-
|
|
NW1439
|
prostate
|
bone
|
-
|
-
|
|
NW1451
|
NSCLC
|
lung
|
-
|
-
|
|
NW1497
|
melanoma
|
lung,
lymph nodes
|
-
|
-
|
|
NW1719
|
prostate
|
bone
|
-
|
-
|
|
NW1720
|
soft
tissue sarcoma
|
peritoneum
|
-
|
-
|
|
NW1721
|
melanoma
|
lung
|
-
|
-
|
|
NW1722
|
NSCLC
|
lung
|
-
|
-
|
|
NW1723
|
NSCLC
|
lung
|
-
|
-
|
|
NW1724
|
melanoma
|
brain,
bone
|
-
|
-
|
aSera
were analyzed for the presence of NY-ESO-1 antibody by Western
blotting at dilutions ranging from 1:250 to 1:10,000. Antibody
reactivity was considered strong (++) when detectable at a serum
dilution of 1:10,000, weak (+) when detectable at a serum dilution
1:250, and negative (-) when no reactivity was detected. Urine
samples were assessed at dilutions ranging from 1:1 to 1:1,000
for the presence of NY-ESO-1 antibody. Antibody reactivity was
considered positive (+) when detectable at a urine dilution of
1:100 and negative (-) when no reactivity was detected in the
undiluted sample. Abbreviations: NSCLC, non-small cell lung cancer;
NEC, neuro-endocrine carcinoma; NHL, non-Hodgkin's lymphoma; SCLC,
small cell lung cancer; CAC, cholangiocellular carcinoma.
|
